Dr. Karthikeshwar Kasirajan

Dr. Karthikeshwar Kasirajan, vascular surgeon and professor at Emory University Hospital in Atlanta, is among the first U.S. physicians to have implanted a Talent Thoracic Stent Graft using the Xcelerant Delivery System. "This combination of a proven stent graft and an advanced delivery system marks a major step forward for the minimally invasive treatment of thoracic aortic aneurysms," Dr. Kasirajan said.

Ultrasound for DVT Ultrasound used in conjunction with clot-busting drugs may be a more effective treatment option for deep vein thrombosis than the use of medications alone to break up clots, according to Karthikeshwar Kasirajan, MD, assistant professor of surgery at the Emory University School of Medicine in Atlanta. Dr. Kasirajan's research team treated 37 patients with a clot-dissolving drug (tissue plasminogen activator, or tPA) and used ultrasound to loosen proteins in blood clots. Sixteen of the 37 patients had DVT and 21 had acute arterial thrombosis. All patients with arterial thrombosis saw their clots dissolve. Ten of the 16 patients with DVT saw clots completely dissolved, four saw partial dissolution and two patients' situations remained unchanged. Only one patient of the 37 experienced a clot-related complication, a neck hematoma. Dr. Kasirajan, who presented his findings on Nov. 23 at the VEITHsymposium in New York City, concludes that the use of ultrasound may help decrease the total dose of lytic agents used.

Karthikeshwar Kasirajan, M.D. Assistant Professor of SurgeryEmory University School of Medicine

"These clots are a main source of both heart attacks and stroke and the more quickly you can eliminate them the better," Dr. Karthikeshwar Kasirajan, an assistant professor of surgery, said in an Emory news release.

In this study, Kasirajan and colleagues treated 37 patients (16 with DVT and 21 with in situ arterial thrombosis) with the clot-busting drug tPA (tissue plasminogen activator), and also used ultrasound to loosen proteins in the blood clots and speed delivery of the drugs into the clots.
...
"We now know that using ultrasound, along with the traditional method of using drugs to break up or dissolve blood clots, will help restore blood flow, prevent valve damage and also prevent the possibility of pulmonary embolism," Kasirajan said.

Each year, 350,000 to 600,000 Americans develop DVT and at least 100,000 of them die, according to the U.S. Surgeon General."These clots are a main source of both heart attacks and stroke and the more quickly you can eliminate them the better," Dr. Karthikeshwar Kasirajan, an assistant professor of surgery, said in an Emory news release.

In this study, Kasirajan and colleagues treated 37 patients (16 with DVT and 21 with in situ arterial thrombosis) with the clot-busting drug tPA (tissue plasminogen activator), and also used ultrasound to loosen proteins in the blood clots and speed delivery of the drugs into the clots.
...
"We now know that using ultrasound, along with the traditional method of using drugs to break up or dissolve blood clots, will help restore blood flow, prevent valve damage and also prevent the possibility of pulmonary embolism," Kasirajan said.

Karthik Kasirajan, MD Emory University School of Medicine

Karthikeshwar Kasirajan, MD Assistant Professor of Surgery Emory University
...
Dr. Kasirajan is a Medtronic Talent Thoracic trainer and Valor II investigator, National P.I. for Talent Thoracic post-market registry

Pre-registration for this Dinner Symposium is required by Tuesday, September 9th.

Karthikeshwar Kasirajan, MD
...
Karthikeshwar Kasirajan, MD

Telephone: 404.778.3470
...
Dr. Kasirajan's Emory Healthcare-based physician profile
...
Dr. Kasirajan's Emory Department of Surgery-based faculty profile

return to top

Dr. Karthikeshwar Kasirajan

BY LI SHENG KONG, MD; KARTHIKESHWAR KASIRAJAN, MD; AND ROSS MILNER, MD
...
Karthikeshwar Kasirajan, MD, is an Assistant Professor of Surgery in the Division of Vascular Surgery, Emory University School of Medicine, Atlanta, Georgia. He holds no financial interest in any product or manufacturer mentioned herein. Dr. Kasirajan may be reached at (404) 727-8407; karthik kasirajan@emoryhealthcare.org.

BOTHELL, WA - November 23, 2008: At the 35th Annual VEITHsymposium (New York, NY), Karthikeshwar Kasirajan, MD, Assistant Professor of Surgery, Emory University School of Medicine, The Emory Clinic (Atlanta, Georgia) presented data on 37 patients treated with catheter-direct pharmacological thrombolysis using recombinant tissue plasminogen activator via the EKOS infusion system.

The study was conducted from December 2006 to August 2008. The purpose of the study was to evaluate the safety and efficacy of ultrasound as an adjunct to facilitate pharmacological thrombolysis. Dr. Kasirajan reported, "All patients received an initial bolus of 2mg of tPA.
...
Kasirajan's study is consistent with the recently published article by Dr. Sanjiv Parikh, et. al. in the April publication of JVIR which reported EKOS-treated patients received half the thrombolytic drug dose or were treated in half the time, or both, when compared to recent historical experience with standard non-ultrasound catheter directed thrombolysis (CDT).